{"id":"https://openalex.org/W7162674751","doi":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps1164","title":"Phase Ib randomized open-label trial of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus nivolumab and relatlimab as second-line therapy metastatic triple negative breast cancer: SIMONE trial.","display_name":"Phase Ib randomized open-label trial of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus nivolumab and relatlimab as second-line therapy metastatic triple negative breast cancer: SIMONE trial.","publication_year":2026,"publication_date":"2026-05-28","ids":{"openalex":"https://openalex.org/W7162674751","doi":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps1164"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2026.44.16_suppl.tps1164","doi":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps1164","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps1164","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2026.44.16_suppl.TPS1164","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2026.44.16_suppl.TPS1164","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5076331410","display_name":"Adriana Matutino Kahn","orcid":"https://orcid.org/0000-0002-5306-0571","observed_orcids":["https://orcid.org/0000-0002-5306-0571"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adriana Matutino Kahn","raw_affiliation_strings":["Yale Cancer Center, Yale School of Medicine, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Center, Yale School of Medicine, New Haven, CT","institution_ids":["https://openalex.org/I2802730090"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050774959","display_name":"Jing Du","orcid":"https://orcid.org/0000-0001-7519-8531","observed_orcids":["https://orcid.org/0000-0001-7519-8531","https://orcid.org/0000-0001-7437-4273","https://orcid.org/0009-0004-7934-7900"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jing Du","raw_affiliation_strings":["Yale School of Medicine, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale School of Medicine, New Haven, CT","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088826700","display_name":"Sarah E. Schellhorn","orcid":"https://orcid.org/0000-0002-8837-1425","observed_orcids":["https://orcid.org/0000-0002-8837-1425"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah Schellhorn","raw_affiliation_strings":["Yale Cancer Center, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Center, New Haven, CT","institution_ids":["https://openalex.org/I2802730090"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5137201448","display_name":"Michael DiGiovanna","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael DiGiovanna","raw_affiliation_strings":["Yale School of Medicine, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale School of Medicine, New Haven, CT","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070648365","display_name":"Wajih Zaheer Kidwai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wajih Kidwai","raw_affiliation_strings":["Yale Shoreline Medical Center, Guilford, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Shoreline Medical Center, Guilford, CT","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078936208","display_name":"Mariya Rozenblit","orcid":"https://orcid.org/0000-0003-0244-429X","observed_orcids":["https://orcid.org/0000-0003-0244-429X"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mariya Rozenblit","raw_affiliation_strings":["Yale Cancer Center, Yale School of Medicine, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Center, Yale School of Medicine, New Haven, CT","institution_ids":["https://openalex.org/I2802730090"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048406793","display_name":"Daniel S. O\u2019Neil","orcid":"https://orcid.org/0000-0002-1779-1166","observed_orcids":["https://orcid.org/0000-0002-1779-1166"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel O'Neil","raw_affiliation_strings":["Yale Cancer Center, Yale University, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Center, Yale University, New Haven, CT","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004476044","display_name":"Robert Duffy Legare","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Duffy Legare","raw_affiliation_strings":["Yale School of Medicine, Westerly, RI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale School of Medicine, Westerly, RI","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042892435","display_name":"Nicole A. Casasanta","orcid":"https://orcid.org/0000-0002-4461-1204","observed_orcids":["https://orcid.org/0000-0002-4461-1204"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicole Casasanta","raw_affiliation_strings":["Yale Cancer Center, Yale School of Medicine, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Center, Yale School of Medicine, New Haven, CT","institution_ids":["https://openalex.org/I2802730090"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114043678","display_name":"Neal A. Fischbach","orcid":"https://orcid.org/0000-0002-5416-9114","observed_orcids":["https://orcid.org/0000-0002-5416-9114"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neal A. Fischbach","raw_affiliation_strings":["Yale Cancer Center, Yale School of Medicine, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Center, Yale School of Medicine, New Haven, CT","institution_ids":["https://openalex.org/I2802730090"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050543825","display_name":"Kathleen M. Fenn","orcid":"https://orcid.org/0000-0001-6327-4365","observed_orcids":["https://orcid.org/0000-0001-6327-4365"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kathleen Marie Fenn","raw_affiliation_strings":["Yale Cancer Center, Trumbull, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Center, Trumbull, CT","institution_ids":["https://openalex.org/I2802730090"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066496998","display_name":"Kim Blenman","orcid":"https://orcid.org/0000-0001-6070-0728","observed_orcids":["https://orcid.org/0000-0001-6070-0728"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kim Blenman","raw_affiliation_strings":["Yale University, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale University, New Haven, CT","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037672574","display_name":"Cristina Naranjo-Ortiz","orcid":"https://orcid.org/0000-0002-2382-3689","observed_orcids":["https://orcid.org/0000-0002-2382-3689"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cristina Naranjo Ortiz","raw_affiliation_strings":["Yale University, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale University, New Haven, CT","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5137297654","display_name":"Wei Wei","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wei Wei","raw_affiliation_strings":["Yale School of Medicine, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale School of Medicine, New Haven, CT","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069547913","display_name":"Julia Mau\u00e9s","orcid":"https://orcid.org/0000-0002-4478-6952","observed_orcids":["https://orcid.org/0000-0002-4478-6952"]},"institutions":[{"id":"https://openalex.org/I4210099632","display_name":"Global and Regional Asperger Syndrome Partnership","ror":"https://ror.org/00zzgy689","country_code":"US","type":"other","lineage":["https://openalex.org/I4210099632"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julia Maues","raw_affiliation_strings":["GRASP, Baltimore, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GRASP, Baltimore, MD","institution_ids":["https://openalex.org/I4210099632"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032785430","display_name":"Ian E. Krop","orcid":"https://orcid.org/0000-0002-6380-5944","observed_orcids":["https://orcid.org/0000-0002-6380-5944"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ian E. Krop","raw_affiliation_strings":["Yale Cancer Center, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Center, New Haven, CT","institution_ids":["https://openalex.org/I2802730090"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070245248","display_name":"Eric P. Winer","orcid":"https://orcid.org/0000-0002-8819-1723","observed_orcids":["https://orcid.org/0000-0002-8819-1723"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric P. Winer","raw_affiliation_strings":["Yale Cancer Center, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Center, New Haven, CT","institution_ids":["https://openalex.org/I2802730090"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086903918","display_name":"Maryam B. Lustberg","orcid":"https://orcid.org/0000-0001-8559-5645","observed_orcids":["https://orcid.org/0000-0001-8559-5645"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maryam B. Lustberg","raw_affiliation_strings":["Yale Cancer Center, Yale School of Medicine, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Center, Yale School of Medicine, New Haven, CT","institution_ids":["https://openalex.org/I2802730090"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5021113979","display_name":"Lajos Pusztai","orcid":"https://orcid.org/0000-0001-9632-6686","observed_orcids":["https://orcid.org/0000-0001-9632-6686"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lajos Pusztai","raw_affiliation_strings":["Yale Cancer Center, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Center, New Haven, CT","institution_ids":["https://openalex.org/I2802730090"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"44","issue":"16_suppl","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9086999893188477,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9086999893188477,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.08079999685287476,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.003100000089034438,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sacituzumab-govitecan","display_name":"sacituzumab govitecan","score":0.9980000257492065},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9789999723434448},{"id":"https://openalex.org/keywords/relatlimab","display_name":"relatlimab","score":1.0},{"id":"https://openalex.org/keywords/metastatic-triple-negative-breast-cancer","display_name":"metastatic triple-negative breast cancer","score":0.8920000195503235},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.753000020980835},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.7799999713897705},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.6890000104904175},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.5889999866485596},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.7900000214576721},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7770000100135803},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.6370000243186951},{"id":"https://openalex.org/keywords/tumor-response","display_name":"tumor response","score":0.4449999928474426}],"concepts":[{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.9474999904632568},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9312000274658203},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.70169997215271},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.699999988079071},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6531000137329102},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.5842000246047974},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5408999919891357},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.48919999599456787},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.48579999804496765},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.40860000252723694},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.3824000060558319},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.350600004196167},{"id":"https://openalex.org/C2780110267","wikidata":"https://www.wikidata.org/wiki/Q7843332","display_name":"Triple-negative breast cancer","level":4,"score":0.3208000063896179},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.28760001063346863},{"id":"https://openalex.org/C2993769353","wikidata":"https://www.wikidata.org/wiki/Q7598360","display_name":"Standard of care","level":2,"score":0.2867000102996826},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.2809000015258789},{"id":"https://openalex.org/C2780775027","wikidata":"https://www.wikidata.org/wiki/Q17141389","display_name":"Salvage therapy","level":3,"score":0.2630999982357025}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2026.44.16_suppl.tps1164","doi":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps1164","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps1164","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2026.44.16_suppl.TPS1164","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1200/jco.2026.44.16_suppl.tps1164","doi":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps1164","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps1164","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2026.44.16_suppl.TPS1164","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9907000064849854,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7162674751.pdf","grobid_xml":"https://content.openalex.org/works/W7162674751.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3166995079","https://openalex.org/W3132703507","https://openalex.org/W3088359096","https://openalex.org/W7122682341","https://openalex.org/W4295836952","https://openalex.org/W7124139116","https://openalex.org/W4403748228","https://openalex.org/W4297680359","https://openalex.org/W4281824652","https://openalex.org/W7223117693"],"abstract_inverted_index":{"TPS1164":[0],"Background:":[1],"The":[2,210,303],"use":[3,254],"of":[4,17,41,73,75,149,181,196,246,265,276,283,311,335,367,369],"immunotherapy":[5,37,51,253],"beyond":[6],"first-line":[7],"setting":[8,258],"is":[9,66,93,109,167,212],"not":[10],"yet":[11],"routine":[12,240],"in":[13,105,204,227,255,315],"the":[14,95,140,146,256,309,380],"treatment":[15,270,383],"arsenal":[16],"patients":[18,100,205,214,233],"with":[19,52,62,101,112,206,242,249,349],"metastatic":[20,102,207,257],"triple-negative":[21],"breast":[22],"cancer":[23],"(TNBC),":[24],"and":[25,104,136,144,179,198,224,289,347,365,371],"this":[26,106],"opens":[27],"an":[28,168,225],"opportunity":[29],"for":[30,99,404],"clinical":[31,337],"trials":[32],"examining":[33],"whether":[34],"adding":[35],"novel":[36],"agents":[38],"to":[39,79,129,176,230],"standard":[40,53,80,96],"care":[42],"therapies":[43],"would":[44],"benefit":[45,338],"patients.":[46],"Prior":[47],"studies":[48],"have":[49],"combined":[50,111],"chemotherapy":[54,81,248],"(Cortes":[55],"J,":[56],"NEJM":[57,86,163],"2022),":[58],"but":[59],"combining":[60],"immunotherapies":[61],"antibody-drug":[63],"conjugates":[64],"(ADCs)":[65],"a":[67,91,191,376,388],"strategy":[68],"worth":[69],"pursuing":[70],"given":[71],"improvement":[72],"outcomes":[74],"ADCs":[76],"when":[77],"compared":[78],"(Bardia":[82],"A":[83],"et":[84,154,161],"al,":[85,155,162],"2021).":[87],"Sacituzumab":[88],"govitecan":[89],"(SG),":[90],"TROP2-ADC,":[92],"currently":[94],"second-line":[97],"therapy":[98],"TNBC,":[103],"study":[107,175,211,382],"it":[108],"being":[110],"either":[113,328],"nivolumab":[114,121,184,197,352,356],"(programmed":[115],"cell":[116],"death":[117],"[PD-1]":[118],"inhibitor)":[119],"or":[120,188,250,259,281,331,353,385],"plus":[122,183,190,342,351,355],"relatlimab":[123,199,358],"(lymphocyte":[124],"activation":[125],"gene-3":[126],"[LAG3]-inhibitor)":[127],"due":[128],"preliminary":[130],"data":[131],"showing":[132],"that":[133],"simultaneous":[134],"PD-1":[135],"LAG3":[137],"inhibition":[138],"enhances":[139],"anti-tumor":[141],"immune":[142],"response":[143,291,324,330,341,370],"restores":[145],"effector":[147],"function":[148],"exhausted":[150],"T-cells":[151],"(Woo":[152],"S-R":[153],"Cancer":[156],"Res":[157],"2012;":[158],"Tawbi":[159],"HA":[160],"2022).":[164],"Methods:":[165],"This":[166],"ongoing":[169],"investigator-initiated":[170],"randomized,":[171],"open-label,":[172],"phase":[173],"Ib":[174],"assess":[177],"safety":[178,307,348],"efficacy":[180],"SG":[182,189,350,354],"(n=":[185],"30":[186,202],"patients)":[187,203],"fixed":[192],"dose":[193],"combination":[194],"(FDC)":[195],"(n":[200],"=":[201],"TNBC;":[208],"NCT06963905.":[209],"accruing":[213],"whose":[215,234],"tumors":[216,235],"are":[217,236],"PD-L1":[218,237],"positive":[219,221],"(combined":[220],"score":[222],">10)":[223],"amendment":[226],"under":[228],"review":[229,399],"also":[231],"include":[232,322,362],"negative":[238],"on":[239],"testing,":[241],"1":[243],"prior":[244,252],"line":[245],"cytotoxic":[247],"without":[251],"within":[260],"6":[261],"months":[262,403],"from":[263],"completion":[264],"curative":[266],"intent":[267],"treatment.":[268],"Study":[269],"will":[271,286,292,374],"be":[272,287,293,375],"continued":[273],"until":[274],"progression":[275],"disease,":[277],"unacceptable":[278],"toxicity,":[279],"death,":[280],"withdrawal":[282],"consent.":[284],"Safety":[285],"monitored,":[288],"tumor":[290],"regularly":[294],"evaluated":[295],"by":[296,396],"RECIST":[297],"1.1":[298],"criteria":[299],"every":[300,401],"9":[301],"weeks.":[302],"primary":[304],"endpoint":[305],"includes":[306],"as":[308,327],"incidence":[310],"dose-limiting":[312],"toxicities":[313],"(DLT)":[314],"3":[316],"weeks":[317],"after":[318,379],"C1D1.":[319],"Secondary":[320],"endpoints":[321,361],"objective":[323],"rate":[325,339],"(defined":[326],"complete":[329],"partial":[332],"response),":[333],"duration":[334],"response,":[336],"(objective":[340],"stable":[343],"disease),":[344],"progression-free":[345],"survival,":[346,364],"+":[357],"FDC.":[359],"Exploratory":[360],"overall":[363],"biomarkers":[366],"prediction":[368],"resistance.":[372],"There":[373],"follow-up":[377,400],"visit":[378],"last":[381],"administration":[384],"before":[386],"starting":[387],"new":[389],"anticancer":[390],"treatment,":[391],"whichever":[392],"occurs":[393],"first,":[394],"followed":[395],"long-term/survival":[397],"chart":[398],"three":[402],"2":[405],"years.":[406],"Clinical":[407],"trial":[408],"information:":[409],"NCT06963905":[410],".":[411]},"counts_by_year":[],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2026-05-29T00:00:00"}